Study on the current situation and technical fields of China's rare disease drug research and developmentJIAO Yang, YAN Jian-zhou, LI Shu-xiang2305-2313
Considerations on use of real-world evidence in regulatory decision-making for rare diseasesZHANG Xiao-min, LIU Xiao-xi, HUANG Zhe2314-2317
The future development trend in the color of solution test for pharmaceutical excipients under the Green Test environmentWANG Hui-juan, HUANG Ting, YANG Yang, HUANG Jia-qi, YANG Rui, YANG Hui-ying2318-2323
Analysis of key considerations in the development of chemical drugs for childrenTU Hui-dan, GUO Zhi-xin, WU Xue-ping, YAO Shang-chen, SUN Chun-meng, QI Shu-ye, NING Bao-ming2324-2330
Development and validation of pyrogen determination in vitro based on THP1-BlueTM NF-κB reporter gene assayWU Yan-lin, ZHANG Ming-lu, YANG Ze-an, CHEN Hong-yu, ZHANG Yuan2331-2337
Screening of high permeability classification tool drugs through PAMPA studiesGUAN Hao-yue, LIU Xue-jing, HUANG Han-han, LIU Qian, ZHANG Zun-jian, NIU Jian-zhao2338-2345
Research progress in positive control samples in container closure integrity test of aseptic preparationsZHU Jia-qi, JIA Fei-fei, ZHAO Xia2346-2351
Combined use of CYP2C19 polymorphism analysis and CRP test to guide the use of voriconazole in the prevention and treatment of invasive fungal infections in patients with hematological diseasesZHOU Li-juan, SANG Zhi-hui, LI Hui-hong, SHEN Ming-hui, GUO Zhi-qiang, HE Meng, QIN Fu-li2352-2358
Tolizumab for the treatment of adolescent patients with aortitis combined with cerebral infarction:a case report and literature reviewYANG Jun, DU Rong, WANG Wei-wei, YUAN Xu-jing2359-2363
Current status of maternal and pediatric drug clinical trial institutions in ChinaYANG Nan, DIAO Sha, HE Si-yi, LIU Zheng, ZHANG Pu-wen, ZENG Li-nan, YU Qin, ZHANG Ling-li2364-2369